Skip Navigation LinksASIC Home > Access For Sight-Impaired Consumers > Resources From A-Z > Health > Canadian Agency for Drugs and Technologies in Health solicits input from patient groups based on feedback from individual patients

Canadian Agency for Drugs and Technologies in Health solicits input from patient groups based on feedback from individual patients

Canadian Agency for Drugs and Technologies in Health  solicits input from individual patients or patient groups
 
Access for Sight Impaired Consumers is pleased to pass on an opportunity to all who are affected by AMD, Choroidal neovascularization (CNV), Diabetic macular edema (DME), Pathologic myopia (PM) and Retinal vein occlusion (RVO) to provide their feedback when treated with Eylea, Avastin, Macuglen and/or Lucentis. The Canadian Agency for Drugs and Technologies in Health is soliciting input from patient groups until Monday June 8 2015. Should you, your family member or volunteer assist you with developing  and submitting your feedback through ASIC, we would recommend you include:
  • your knowledge or awareness of which drug therapy was being used by your ophthalmologist;
  • Did your ophthalmologist switch drug therapies from one treatment to another?
  • Were you provided with a choice of drug therapies?
  • Did your ophthalmologist provide full disclosure about the drug therapy you were being treated with?
  • If you experienced a switch in medications from one treatment to another, did you find one medication provided better results over the other?
  • Did you experience any side or ill effects using any of the medications?
Details of the study are included below. You can participate by sending your feedback to info@asicbc.ca.
 
Anti–Vascular Endothelial Growth Factor Drugs for Retinal Conditions
Published on: May 5, 2015
Project Number: TR0009
Product Line: Therapeutic Review
 
With the aging Canadian population, retinal conditions are likely to be increasingly encountered in clinical practice. Drugs acting on a protein called vascular endothelial growth factor (VEGF) have been shown to be effective in the treatment of these conditions. Whether the use of these drugs results in important clinical differences is unclear. In addition, the use of Avastin (bevacizumab) (initially designed to treat cancer) is associated with significantly lower cost, compared to the other anti-VEGF drugs; e.g. treating the retinal condition age-related macular degeneration (AMD) may be associated with expenditures that are 30 times lower.
 
CADTH is undertaking a therapeutic review comparing the clinical and economic effectiveness of anti-VEGF drugs including Eylea (Aflibercept), Avastin (Bevacizumab), Macugen (Pegaptanib) and Lucentis (Ranibizumab) for the treatment of the following retinal conditions:
  • AMD
  • Choroidal neovascularization (CNV)
  • Diabetic macular edema (DME)
  • Pathologic myopia (PM) and
  • Retinal vein occlusion (RVO)
The therapeutic review project will include a science report (clinical and economic evaluations) and a recommendations report.

Patient Input

CADTH solicits input from individual patients and patient groups to ensure that health outcomes and issues important to patients are incorporated into the review process in a formal and meaningful way.

Now open!

Individual patients and organized patient groups are invited to complete the patient input template. Please return to feedback@cadth.ca by Monday June 8, 2015.

Back to top of page